Chronic low-grade inflammation is a key driver of cardiovascular disease, even when cholesterol is controlled. The ACC’s 2025 Scientific Statement highlights hsCRP as a routine risk marker and outlines lifestyle and pharmacologic anti-inflammatory strategies for prevention and treatment.